14 Perspectives of Aptamers for Medical Applications
455
133. zur Hausen H (2002) Papillomaviruses and cancer: from basic studies to clinical application.
Nat Rev Cancer 2(5):342–350. https://doi.org/10.1038/nrc798
134. Bose P, Grant S (2015) Rational combinations of targeted agents in AML. J Clin Med 4(4):634–
664. https://doi.org/10.3390/jcm4040634
135. Stuart R, Stockerl-Goldstein K, Cooper M, Devetten M, Herzig R, Medeiros B, Schiller G, Wei
A, Acton G, Rizzieri D (2009) Randomized phase II trial of the nucleolin targeting aptamer
AS1411 combined with high-dose cytarabine in relapsed/refractory acute myeloid leukemia
(AML). Journal of clinical oncology 27(15_suppl):7019–7019
136. Bates PJ, Reyes-Reyes EM, Malik MT, Murphy EM, O’Toole MG, Trent JO (2017) Gquadruplex oligonucleotide AS1411 as a cancer-targeting agent: Uses and mechanisms.
Biochim Biophys Acta Gen Subj 1861(5 Pt B):1414–1428. https://doi.org/10.1016/j.bbagen.
2016.12.015
137. Shangguan D, Li Y, Tang Z, Cao ZC, Chen HW, Mallikaratchy P, Sefah K, Yang CJ, Tan W
(2006) Aptamers evolved from live cells as effective molecular probes for cancer study. Proc
Natl Acad Sci U S A 103(32):11838–11843. https://doi.org/10.1073/pnas.0602615103
138. Shangguan D, Tang Z, Mallikaratchy P, Xiao Z, Tan W (2007) Optimization and modifications
of aptamers selected from live cancer cell lines. ChemBioChem 8(6):603–606. https://doi.org/
10.1002/cbic.200600532
139. Shangguan D, Cao Z, Meng L, Mallikaratchy P, Sefah K, Wang H, Li Y, Tan W (2008) Cellspecific aptamer probes for membrane protein elucidation in cancer cells. J Proteome Res
7(5):2133–2139. https://doi.org/10.1021/pr700894d
140. Huang YF, Shangguan D, Liu H, Phillips JA, Zhang X, Chen Y, Tan W (2009) Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells.
ChemBioChem 10(5):862–868. https://doi.org/10.1002/cbic.200800805
141. Mori T, Oguro A, Ohtsu T, Nakamura Y (2004) RNA aptamers selected against the receptor
activator of NF-kappaB acquire general affinity to proteins of the tumor necrosis factor
receptor family. Nucl Acids Res 32(20):6120–6128. https://doi.org/10.1093/nar/gkh949
142. Hsu FY, Zhao Y, Anderson WF, Johnston PB (2007) Downregulation of NPM-ALK by siRNA
causes anaplastic large cell lymphoma cell growth inhibition and augments the anti cancer
effects of chemotherapy in vitro. Cancer Invest 25(4):240–248. https://doi.org/10.1080/073
57900701206372
143. Zhao N, You J, Zeng Z, Li C, Zu Y (2013) An ultra pH-sensitive and aptamer-equipped
nanoscale drug-delivery system for selective killing of tumor cells. Small 9(20):3477–3484.
https://doi.org/10.1002/smll.201202694
144. Parekh P, Kamble S, Zhao N, Zeng Z, Portier BP, Zu Y (2013) Immunotherapy of CD30expressing lymphoma using a highly stable ssDNA aptamer. Biomaterials 34(35):8909–8917.
https://doi.org/10.1016/j.biomaterials.2013.07.099
145. Yang S, Li H, Xu L, Deng Z, Han W, Liu Y, Jiang W, Zu Y (2018) Oligonucleotide aptamermediated precision therapy of hematological malignancies. Mol Ther Nucl Acids 13:164–175.
https://doi.org/10.1016/j.omtn.2018.08.023
146. Siegel RL, Miller KD (2020) Jemal A (2020) Cancer statistics. CA Cancer J Clin 70(1):7–30.
https://doi.org/10.3322/caac.21590
147. DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, Jemal A, Siegel
RL (2019) Breast cancer statistics. CA Cancer J Clin 69(6):438–451. https://doi.org/10.3322/
caac.21583
148. Liu Z, Duan JH, Song YM, Ma J, Wang FD, Lu X, Yang XD (2012) Novel HER2 aptamer
selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro. J Transl Med
10:148. https://doi.org/10.1186/1479-5876-10-148
149. Konry T, Hayman RB, Walt DR (2009) Microsphere-based rolling circle amplification
microarray for the detection of DNA and proteins in a single assay. Anal Chem 81(14):5777–
5782. https://doi.org/10.1021/ac900694y
150. Chu M, Kang JR, Wang W, Li H, Feng JH, Chu ZY, Zhang MB, Xu L, Wang YD (2017)
Evaluation of human epidermal growth factor receptor 2 in breast cancer with a novel specific
aptamer. Cell Mol Immunol 14(4):398–400. https://doi.org/10.1038/cmi.2015.31
455
133. zur Hausen H (2002) Papillomaviruses and cancer: from basic studies to clinical application.
Nat Rev Cancer 2(5):342–350. https://doi.org/10.1038/nrc798
134. Bose P, Grant S (2015) Rational combinations of targeted agents in AML. J Clin Med 4(4):634–
664. https://doi.org/10.3390/jcm4040634
135. Stuart R, Stockerl-Goldstein K, Cooper M, Devetten M, Herzig R, Medeiros B, Schiller G, Wei
A, Acton G, Rizzieri D (2009) Randomized phase II trial of the nucleolin targeting aptamer
AS1411 combined with high-dose cytarabine in relapsed/refractory acute myeloid leukemia
(AML). Journal of clinical oncology 27(15_suppl):7019–7019
136. Bates PJ, Reyes-Reyes EM, Malik MT, Murphy EM, O’Toole MG, Trent JO (2017) Gquadruplex oligonucleotide AS1411 as a cancer-targeting agent: Uses and mechanisms.
Biochim Biophys Acta Gen Subj 1861(5 Pt B):1414–1428. https://doi.org/10.1016/j.bbagen.
2016.12.015
137. Shangguan D, Li Y, Tang Z, Cao ZC, Chen HW, Mallikaratchy P, Sefah K, Yang CJ, Tan W
(2006) Aptamers evolved from live cells as effective molecular probes for cancer study. Proc
Natl Acad Sci U S A 103(32):11838–11843. https://doi.org/10.1073/pnas.0602615103
138. Shangguan D, Tang Z, Mallikaratchy P, Xiao Z, Tan W (2007) Optimization and modifications
of aptamers selected from live cancer cell lines. ChemBioChem 8(6):603–606. https://doi.org/
10.1002/cbic.200600532
139. Shangguan D, Cao Z, Meng L, Mallikaratchy P, Sefah K, Wang H, Li Y, Tan W (2008) Cellspecific aptamer probes for membrane protein elucidation in cancer cells. J Proteome Res
7(5):2133–2139. https://doi.org/10.1021/pr700894d
140. Huang YF, Shangguan D, Liu H, Phillips JA, Zhang X, Chen Y, Tan W (2009) Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells.
ChemBioChem 10(5):862–868. https://doi.org/10.1002/cbic.200800805
141. Mori T, Oguro A, Ohtsu T, Nakamura Y (2004) RNA aptamers selected against the receptor
activator of NF-kappaB acquire general affinity to proteins of the tumor necrosis factor
receptor family. Nucl Acids Res 32(20):6120–6128. https://doi.org/10.1093/nar/gkh949
142. Hsu FY, Zhao Y, Anderson WF, Johnston PB (2007) Downregulation of NPM-ALK by siRNA
causes anaplastic large cell lymphoma cell growth inhibition and augments the anti cancer
effects of chemotherapy in vitro. Cancer Invest 25(4):240–248. https://doi.org/10.1080/073
57900701206372
143. Zhao N, You J, Zeng Z, Li C, Zu Y (2013) An ultra pH-sensitive and aptamer-equipped
nanoscale drug-delivery system for selective killing of tumor cells. Small 9(20):3477–3484.
https://doi.org/10.1002/smll.201202694
144. Parekh P, Kamble S, Zhao N, Zeng Z, Portier BP, Zu Y (2013) Immunotherapy of CD30expressing lymphoma using a highly stable ssDNA aptamer. Biomaterials 34(35):8909–8917.
https://doi.org/10.1016/j.biomaterials.2013.07.099
145. Yang S, Li H, Xu L, Deng Z, Han W, Liu Y, Jiang W, Zu Y (2018) Oligonucleotide aptamermediated precision therapy of hematological malignancies. Mol Ther Nucl Acids 13:164–175.
https://doi.org/10.1016/j.omtn.2018.08.023
146. Siegel RL, Miller KD (2020) Jemal A (2020) Cancer statistics. CA Cancer J Clin 70(1):7–30.
https://doi.org/10.3322/caac.21590
147. DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, Jemal A, Siegel
RL (2019) Breast cancer statistics. CA Cancer J Clin 69(6):438–451. https://doi.org/10.3322/
caac.21583
148. Liu Z, Duan JH, Song YM, Ma J, Wang FD, Lu X, Yang XD (2012) Novel HER2 aptamer
selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro. J Transl Med
10:148. https://doi.org/10.1186/1479-5876-10-148
149. Konry T, Hayman RB, Walt DR (2009) Microsphere-based rolling circle amplification
microarray for the detection of DNA and proteins in a single assay. Anal Chem 81(14):5777–
5782. https://doi.org/10.1021/ac900694y
150. Chu M, Kang JR, Wang W, Li H, Feng JH, Chu ZY, Zhang MB, Xu L, Wang YD (2017)
Evaluation of human epidermal growth factor receptor 2 in breast cancer with a novel specific
aptamer. Cell Mol Immunol 14(4):398–400. https://doi.org/10.1038/cmi.2015.31